{"id":"NCT02284893","sponsor":"AstraZeneca","briefTitle":"Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone","officialTitle":"A 26-week International, Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group, Phase 3bTrial With a Blinded 26-week Long -Term Extension Period to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-09-09","primaryCompletion":"2016-09-20","completion":"2016-09-20","firstPosted":"2014-11-06","resultsPosted":"2018-06-01","lastUpdate":"2018-06-01"},"enrollment":461,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes"],"interventions":[{"type":"DRUG","name":"Saxagliptin","otherNames":[]},{"type":"DRUG","name":"Dapagliflozin","otherNames":[]},{"type":"DRUG","name":"Sitagliptin","otherNames":[]},{"type":"DRUG","name":"Placebo matching with Saxagliptin","otherNames":[]},{"type":"DRUG","name":"Placebo matching with Dapagliflozin","otherNames":[]},{"type":"DRUG","name":"Placebo matching with Sitagliptin","otherNames":[]}],"arms":[{"label":"A1:Saxagliptin / Placebo + Dapagliflozin / Placebo","type":"EXPERIMENTAL"},{"label":"A2: Sitagliptin / placebo","type":"EXPERIMENTAL"}],"summary":"Study will evaluate if a combination of saxagliptin and dapagliflozin added concurrently to metformin in combination with diet and exercise is superior to sitagliptin added to metformin in combination with diet and exercise in reducing mean HbA1c over a treatment period of 26 weeks.","primaryOutcome":{"measure":"Mean Change in HbA1c","timeFrame":"Baseline (randomization) to Week 26","effectByArm":[{"arm":"Saxagliptin + Dapagliflozin + Metformin Group","deltaMin":-1.41,"sd":0.0696},{"arm":"SITA + MET","deltaMin":-1.07,"sd":0.0719}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0008"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":8},"locations":{"siteCount":79,"countries":["United States","Hungary","Mexico","Poland","Romania","South Africa"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":232},"commonTop":["NASOPHARYNGITIS","HEADACHE","INFLUENZA","URINARY TRACT INFECTION","UPPER RESPIRATORY TRACT INFECTION"]}}